Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML - HSA Drug Approval Details

Approvals/HSA/ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML

Approved

THERAPEUTIC

ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML

Catalent Indiana, LLCAlexion Pharma International Operations Limited (AAMF)🇸🇬 Health Sciences Authority

Approval Date: Jun 19, 2024
Approval ID: a8382625259a6329
Company: Catalent Indiana, LLCAlexion Pharma International Operations Limited (AAMF)
Type: Therapeutic

Approval Details

Approval Id: a8382625259a6329
Drug Name: ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML
Product Name: ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML
Approval Number: SIN17026P
Approval Date: 2024-06-19
Registrant: ASTRAZENECA SINGAPORE PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INFUSION, SOLUTION CONCENTRATE
Route Of Administration: INTRAVENOUS
Atc Code: L04AA43
Pharma Manufacturer Name: ASTRAZENECA SINGAPORE PTE LTD
Company Detail Path: /organization/469fa28f5ad70b79/astrazeneca-singapore-pte-ltd

Active Ingredients

Ravulizumab

100 mg/mL

Ravulizumab

100 mg/mL

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 19, 2024

Approval ID

a8382625259a6329

Type

Therapeutic

Back to HSA Approvals